Twice-Daily 0.2% Brimonidine–0.5% Timolol Fixed-Combination Therapy vs Monotherapy With Timolol or Brimonidine in Patients With Glaucoma or Ocular Hypertension

Combination Products in Clinical Practice: Canadian Experience

“…In this group, the incidence of allergy with Combigan was approximately half that typically seen with its constituent agent, Alphagan. This mirrors the findings of the Phase III study by Craven et al and Sherwood et al in the United States, where the rate of allergic conjunctivitis for Combigan was almost half that for Alphagan (5.2% vs 9.4%) (3,4).…”

Combination Products in Clinical Practice: Canadian Experience

“…In this group, the incidence of allergy with Combigan was approximately half that typically seen with its constituent agent, Alphagan. This mirrors the findings of the Phase III study by Craven et al and Sherwood et al in the United States, where the rate of allergic conjunctivitis for Combigan was almost half that for Alphagan (5.2% vs 9.4%) (3,4).…”

Fixed Triple-Combination Bimatoprost/Brimonidine/Timolol Versus Separate Administration in Glaucoma: Randomized Clinical Trial

“…This finding contrasts with some reports in the glaucoma literature, where fixed combinations were associated with a lower incidence of hyperemia compared with unfixed regimens. 17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31 Notably, patients who discontinued treatment exhibited higher baseline grades of hyperemia, suggesting that a more compromised ocular surface may increase susceptibility to adverse events.…”

“…17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31 Notably, patients who discontinued treatment exhibited higher baseline grades of hyperemia, suggesting that a more compromised ocular surface may increase susceptibility to adverse events. Cumulative exposure to BAK, common to both regimens despite the expected higher cumulative dose in the unfixed group, may also have contributed to the increase in hyperemia.…”

“…17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31…”

Preliminary results following the use of a fixed combination of timolol–brimonidine in patients with ocular hypertension and primary open-angle glaucoma

“……”

Combination Products in Clinical Practice: Canadian Experience

“…In this group, the incidence of allergy with Combigan was approximately half that typically seen with its constituent agent, Alphagan. This mirrors the findings of the Phase III study by Craven et al and Sherwood et al in the United States, where the rate of allergic conjunctivitis for Combigan was almost half that for Alphagan (5.2% vs 9.4%) (3,4).…”

Fixed Triple-Combination Bimatoprost/Brimonidine/Timolol Versus Separate Administration in Glaucoma: Randomized Clinical Trial

“…This finding contrasts with some reports in the glaucoma literature, where fixed combinations were associated with a lower incidence of hyperemia compared with unfixed regimens. 17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31 Notably, patients who discontinued treatment exhibited higher baseline grades of hyperemia, suggesting that a more compromised ocular surface may increase susceptibility to adverse events.…”

“…17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31 Notably, patients who discontinued treatment exhibited higher baseline grades of hyperemia, suggesting that a more compromised ocular surface may increase susceptibility to adverse events. Cumulative exposure to BAK, common to both regimens despite the expected higher cumulative dose in the unfixed group, may also have contributed to the increase in hyperemia.…”

“…17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31…”

Preliminary results following the use of a fixed combination of timolol–brimonidine in patients with ocular hypertension and primary open-angle glaucoma

“……”

Combination Products in Clinical Practice: Canadian Experience

“…In this group, the incidence of allergy with Combigan was approximately half that typically seen with its constituent agent, Alphagan. This mirrors the findings of the Phase III study by Craven et al and Sherwood et al in the United States, where the rate of allergic conjunctivitis for Combigan was almost half that for Alphagan (5.2% vs 9.4%) (3,4).…”

Fixed Triple-Combination Bimatoprost/Brimonidine/Timolol Versus Separate Administration in Glaucoma: Randomized Clinical Trial

“…This finding contrasts with some reports in the glaucoma literature, where fixed combinations were associated with a lower incidence of hyperemia compared with unfixed regimens. 17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31 Notably, patients who discontinued treatment exhibited higher baseline grades of hyperemia, suggesting that a more compromised ocular surface may increase susceptibility to adverse events.…”

“…17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31 Notably, patients who discontinued treatment exhibited higher baseline grades of hyperemia, suggesting that a more compromised ocular surface may increase susceptibility to adverse events. Cumulative exposure to BAK, common to both regimens despite the expected higher cumulative dose in the unfixed group, may also have contributed to the increase in hyperemia.…”

“…17,18 In our study, hyperemia was the most prevalent ocular adverse event and likely had a relevant impact on tolerability and persistence, consistent with previous trials of combinations containing bimatoprost and brimonidine. 17,18,31…”

Preliminary results following the use of a fixed combination of timolol–brimonidine in patients with ocular hypertension and primary open-angle glaucoma

“……”